September 23, 2009 3:27 PM
- Text
GSK's New MECC Ban Is Full of Holes, Says Carlat
(MoneyWatch) GlaxoSmithKline has tightened its rules for funding of continuing medical education, but psychiatrist blogger Daniel Carlat says the ban is full of holes. Carlat is conducting a jihad against CME, which he regards as a form of "money-laundering."
GSK banned funding of "medical education and comunication companies," or MECCs, which have come to be regarded as little more than pr agencies that specialize in focus groups with doctors. The company has also ceased its political donations. The moves come as part of GSK's ongoing transparency push.
GSK's press release says:
Carlat argues that far from being a ban on MECCs, GSK's new policy simply adds another figleaf to the operation and allows GSK to claim that its funding does not result in seminars that are biased toward its drugs. (He has a more in-depth view of GSK's MECC funding here, and notes that GSK is still soliciting grant recipients here.)
GSK banned funding of "medical education and comunication companies," or MECCs, which have come to be regarded as little more than pr agencies that specialize in focus groups with doctors. The company has also ceased its political donations. The moves come as part of GSK's ongoing transparency push.
GSK's press release says:
GSK will no longer fund CME by commercial providers including medical education and communication companies.But Carlat says the ban has loopholes in that it still allows "co-sponsorship," where one of the remaining institutions that GSK will still fund can hire a MECC to create a CME course. GSK will continue to fund colleges and medical societies.
Carlat argues that far from being a ban on MECCs, GSK's new policy simply adds another figleaf to the operation and allows GSK to claim that its funding does not result in seminars that are biased toward its drugs. (He has a more in-depth view of GSK's MECC funding here, and notes that GSK is still soliciting grant recipients here.)
- Previously:
- In TBWA's New Ads for GSK's Alli, Loss of Bowel Control Is No Longer a Problem
- GSK to Alli Users With Liver Damage: "This Might Be Your Fault, Fatty"
- FDA Warning Ushers GSK's Alli Toward Graveyard of Failed Obesity Products
- "CASSPER" Was GSK's Friendly Ghostwriting Program on Paxil
- Allergan Gets on the GSK Merry-Go-Round for a Second Time
- The FDA Gives GSK a New Way to Tout Alli
- GSK and Centocor Abandon Their Pioneering Corporate Drug Blogs
- GSK Signs Wynonna Judd to Endorse Alli, Its Flagging Weight Loss Drug
- GSK's Alli Diet Drug Has Problems With Your "Fat Friend"
Latest Now in MoneyWatch
- Insurers respond cautiously to contraceptive plan
- Judge: Legally, breastfeeding not related to pregnancy
- Budget deficit drops to $27 billion in January
- Why the Powerball Jackpot is part of my investment strategy
- Is the new VW Beetle diesel worth the money?
- Consumer sentiment highlights risks to recovery
- Valentine blues? 10 best cities to be single
- December trade deficit widens to $48.8 billion
- Alcatel-Lucent returns to profit in 2011
- 6 things never to say in a performance review
- $26B mortgage deal: Who gets the money?
- Friendly's CEO steps down
- Quarterly loss hits $3.3B at Postal Service
- Greeks rail against cuts as EU demands more
- 6 things you should never share on Facebook
- Make moves now to increase financial aid
- Valentine's Day: 9 places to save
Latest CBS News Headlines
on Facebook
on CBS News
- NH 14-year-old shoots self in face in cafeteria
- Dad of NYC subway bomb plotter gets prison time
- NH 14-year-old shoots self in face in cafeteria
- Ginsburg questions 1973 abortion ruling's timing
on Facebook
- Adele sings a cappella for Anderson Cooper
- Josh Powell had "incestuous" images on his home computer, authorities say
on CBS News






